key: cord-0747779-gryl2s3i authors: Velázquez, Argentina Colmenero; Esteso, Gloria; del Rosal, Teresa; Apalategui, Ane Calvo; Reyburn, Hugh; López-Granados, Eduardo title: Marked changes in innate immunity associated with a mild course of COVID-19 in identical twins with athymia and absent circulating T cells date: 2020-12-03 journal: J Allergy Clin Immunol DOI: 10.1016/j.jaci.2020.11.007 sha: 2fe53d676fac365392d3d635cb0d6948f103b6e9 doc_id: 747779 cord_uid: gryl2s3i nan Marked changes in innate immunity associated with a mild course of COVID-19 in identical twins with athymia and absent circulating T cells Q 1 To the Editor: We read with interest the articles from Casanova et al Q 2 revealing impaired type I IFN immunity as a major risk for severe coronavirus disease 2019 (COVID-19) 1,2 ; however, the relative importance of innate and adaptive immunity for viral control is difficult to evaluate. 3 A diagnosis of mild COVID-19 in 2 identical twin neonates with an uncommon PID Q 3 that causes athymia and almost complete T-cell lymphopenia allowed study of innate immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the absence of adaptive immunity. Identical male twins were born at 3614 weeks of gestation to nonconsanguineous parents. Diarrhea in both prompted admission to the neonatology department. Routine cerebral ultrasounds revealed white matter hyperechogenicity in both, and congenital cytomegalovirus (CMV) was diagnosed. At 13 days of life, both presented self-limited fever and mild cough and nosocomial SARS-CoV-2 infection was suspected and PCR confirmed. Unfortunately, the PCR-positive samples were not stored, and so a more detailed molecular characterization of the virus in these infants is impossible. The absence of a detailed virological analysis of the SARS-CoV-2 detected in these children and the possible confounding effects of coinfection with HCMV , A), with no recent thymic migrants. Retrospective analysis of Guthrie cards revealed undetectable TRECs, but normal KRECs , hypoparathyroidism, severe hypocalcemia, and hyperphosphatemia suggested Di George syndrome. Analysis of a customized NGS Q 7 panel for primary immunodeficiencies identified a mutant TBX1 gene allele with c.1170_1176del, p.G391PfsTer67 and c.1163C>T, p.A388V de novo variants (pathogenic and probably pathogenic, respectively). No other pathogenic variants were found in known genes associated with immunodeficiency. Surprisingly, clinical signs of SARS-CoV-2 infection resolved within 2 weeks, with negative PCRs. Because almost no T cells, and only naive B cells, were present, innate immunity to SARS-CoV-2 was investigated. A strong signature of type I interferonstimulated genes (ISGs) (Fig 1, B) was detected in blood cells, which diminished rapidly, notwithstanding persistent CMV replication despite antiviral treatment (Online Repository data available on request). These data suggest that ISG induction was likely driven by SARS-CoV-2, rather than CMV, infection; however, in the absence of data from other SARS-CoV-2 1 , CMV 2 , T-cell-deficient newborns, we cannot completely exclude that either the treatment or the CMV infection itself may have modulated some ISG expression. Indeed, it is possible that the congenital CMV infection primed innate immunity for more effective suppression of SARS-CoV-2 replication. No marked changes in major lymphocyte populations were noted (Fig 1, C) until 26 days after positive PCR, when a population of activated NK cells appeared in peripheral blood (Online Repository data available on request). Strikingly, upregulation Q 8 of the NKG2C receptor on essentially all CD56 dim NK cells was observed (Fig 1, D) that generally did not coexpress CD57, unlike the NKG2C-expressing NK cells associated with CMV infection. 4 The spontaneous recovery of these T-cell-deficient infants from SARS-CoV-2 infection supports the idea that innate immune mechanisms are important for immune control of this virus. 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Immunology of COVID-19: current state of the science Expansion of a unique CD57(1)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients